Polarean Imaging PLC Board appointment (8077P)
22 Febrero 2021 - 1:00AM
UK Regulatory
TIDMPOLX
RNS Number : 8077P
Polarean Imaging PLC
22 February 2021
Polarean Imaging Plc
("Polarean" or the "Company")
Board appointment
Polarean Imaging plc (AIM: POLX), the medical--imaging
technology company, with a proprietary drug--device combination
product using hyperpolarised xenon-129 gas to enhance magnetic
resonance imaging (MRI) in pulmonary medicine, announces the
appointment of Charles ("Chuck") Fremont Osborne Jr. to the Board
with immediate effect.
Chuck joined Polarean in April 2019 as Chief Financial Officer
("CFO"). He was previously at Innocrin Pharmaceuticals Inc
("Innocrin"), a privately held oncology therapeutics company where
he was CFO since 2015. Prior to his role at Innocrin, Chuck was CFO
of Scynexis Inc, a publicly traded anti-infective company between
2003 and 2015. Chuck holds a Bachelor of Science degree in Business
Administration, with a Concentration in Accounting, from University
of North Carolina. He is a Certified Public Accountant and began
his accounting career at Deloittie & Touche in 1988.
Richard Hullihen, CEO of Polarean Imaging, commented: "Chuck has
been an invaluable addition to the team since his appointment in
2019, and this next step to take a position on the Board is a
natural one. Chuck has significant capital markets experience
coupled with a strong knowledge of financial operations within the
pharmaceutical industry, and we welcome him to the Board ahead of
the next phase of Polarean's lifecycle."
The following information regarding the appointment of Charles
Osborne (aged 55) is required to be disclosed under Rule 17,
Schedule 2(g) of the AIM Rules for Companies:
Current directorships/partnerships: None
Directorships and partnerships held within the last five years:
None
Shareholding: Charles Osborne holds 1,200,000 options over
ordinary shares of the Company.
Save for the information set out above, there are no further
disclosures to be made in respect of the appointment of Charles
Osborne.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Via Walbrook PR
Officer
Jonathan Allis, Chairman
Stifel Nicolaus Europe Limited (NOMAD and
Sole Corporate Broker) +44 (0)20 7710 7600
Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare
Investment Banking)
Nick Adams / Fred Walsh (Corporate
Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7876
741 001
About Polarean ( www.polarean.com )
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue generating, medical drug-device
combination companies operating in the high resolution medical
imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation and gas exchange regionally
in the smallest airways of the lungs, the tissue barrier between
the lung and the bloodstream and in the pulmonary vasculature.
Xenon gas exhibits solubility and signal properties that enable it
to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel diagnostic approach,
offering a non-invasive and radiation-free functional imaging
platform which is more accurate and less harmful to the patient
than current methods. The annual burden of pulmonary disease in the
US is estimated to be over US$150 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAZZGZZMGNGMZM
(END) Dow Jones Newswires
February 22, 2021 02:00 ET (07:00 GMT)
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024